Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Abstract

Abstract Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.

Keywords

• larotrectinib
• neoadjuvant
• NTRK gene fusions
• soft tissue sarcoma